view of the mountains in Denver, Colorado

- Research

2 MIN

A spotlight on migraine at the upcoming AHS 2022 Annual Scientific Meeting

The 64th Annual Scientific Meeting of the American Headache Society® (AHS) is a live and virtual event running from June 9–12. This meeting, aimed at physicians, psychologists, scientists, and other healthcare professionals who care for patients with head, neck, and orofacial pain, will take place in Denver, Colorado. The theme for this year’s meeting is ‘Making Connections’, and AHS 2022 will provide great opportunities for networking with colleagues, as well as getting up to date with cutting-edge research developments. This article outlines key events at this year’s AHS meeting, with a focus on migraine.

Click here for more information on AHS 2022

Symposia of interest:

Pacific Rim Symposium: How are CGRP-Related Monoclonal Antibodies Changing Migraine Therapy in the Pacific Rim Countries?
Thursday, June 9 | 10:30 AM – 12:30 PM MDT 
This session, moderated by Mamoru Shibata from Tokyo, will provide an overview of the use of CGRP pathway antibodies in migraine prophylaxis. The speakers, Yen-Feng Wang, Michael Eller, Hong-Kyun Park, and Daisuke Danno, will present valuable real-world insight regarding the use of these agents in Taiwan, Australia, Japan, and South Korea.

Join the conversation on Twitter!
#TevaCNS
#AHSAM22
#CnsBytes
#Tevamigraine

Sessions of interest to look out for:

  • Member’s Choice Award: Management of Primary Headaches During Pregnancy, Postpartum, and Breastfeeding: A Systematic Review. Thursday, June 9, 4:45 – 5:30 PM MDT | Kenneth K. Chen, Brown University.
  • OR-08: Symptoms of Increased Peripheral and Central Trigeminal Sensitization Predict the Response to anti-CGRP Monoclonal Antibodies: A Multicenter, 24-Week, Cohort Study on 864 Migraine Patients. Friday, June 10, 12:25 – 12:35 PM MDT | Gabriella Egeo, IRCCS San Raffaele Roma.
  • IOR-02: Incidences of Traumatic Brain Injury and Post-Traumatic Headache for all Age Groups Using a US Claims Database. Saturday, June 11, 7:40 – 7:50 AM MDT | Juline Bryson, Teva.
  • IOR-05: Characterizing Preventive Treatment Gaps in Migraine: Interim Results From the CaMEO-International Study United States Sample. Saturday, June 11, 8:10 – 8:20 AM MDT | Dawn C. Buse, Albert Einstein College of Medicine.
  • Late-breaking abstract: FOCUS obesity and difficult-to-treat migraine. Saturday, June 11, 11:15 – 11:55 AM MDT | Presenter TBC.
  • Plenary Session: What Makes Migraine Worse? Saturday, June 11, 3:45 – 5:45 PM MDT.
    This session, which is moderated by Dawn C. Buse and chaired by Amynah A. Pradhan, will look at key factors that influence the severity of migraine. Presentations from Eric A. Kaiser, Emily Law, Todd J. Schwedt, Dale S. Bond, and Todd A. Smitherman will explore the effects of sleep, medication overuse, obesity, and psychiatric comorbidities on migraine.

Related articles: